Tech Company Financing Transactions
Transcept Pharmaceuticals Funding Round
Apax Partners, Domain Associates and New Enterprise Associates participated in a $25 million Series C venture round for Transcept Pharmaceuticals. The financing was announced on 1/4/2006.
Transaction Overview
Company Name
Announced On
1/4/2006
Transaction Type
Venture Equity
Amount
$25,000,000
Round
Series C
Investors
Proceeds Purpose
The Company will use this additional funding primarily to launch its Phase 3 clinical trial with DN-101 in advanced prostate cancer.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
75 Park Plz. 4th Floor
Boston, MA 02116
USA
Boston, MA 02116
USA
Phone
Website
Email Address
Overview
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Bigham
Chief Financial Officer
Douglas Pagán
Chief Medical Officer
Evan Loh
President
Adam Woodrow
Browse more venture capital transactions:
Prev: 1/4/2006: EZ Prints venture capital transaction
Next: 1/5/2006: XDx venture capital transaction
Share this article
Where The Data Comes From
We document every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs